2022 CDC Clinical Practice Guideline for Prescribing Opioids Implementation Guide
2022.1.0 - CI Build

2022 CDC Clinical Practice Guideline for Prescribing Opioids Implementation Guide, published by Centers for Disease Control and Prevention (CDC). This guide is not an authorized publication; it is the continuous build for version 2022.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/cqframework/opioid-cds-r4/ and changes regularly. See the Directory of published versions

Recommendation #8 - Naloxone Consideration

CDC Guideline: 2022 CDC Clinical Practice Guideline for Prescribing Opioids for Pain
Recommendation Topic: Assessing Risk and Addressing Potential Harms of Opioid Use (Source)
Recommendation Description: Before starting and periodically during continuation of opioid therapy, clinicians should evaluate risk for opioid-related harms and discuss risk with patients. Clinicians should work with patients to incorporate into the management plan strategies to mitigate risk, including offering naloxone. (Source)
Recommendation Category: A
Evidence Type: 4
Recommendation08-flow.png
Flow Diagram for Recommendation 8

  • When
    • Order for opioid analgesics with ambulatory misuse potential:
    • Opioid review is useful for this patient:
      • Patient is 18 or over
      • Patient does not have evidence of sickle cell disease
      • Patient does not have findings indicating limited life expectancy
      • Patient does not have orders for therapies indicating end of life care
      • Patient is not undergoing active cancer treatment:
        • Patient has had at least 2 office visits within the past 12 months with an oncology specialist present, or
        • Patient has had at least 2 office visits within the past 12 months with a CDC malignant cancer condition diagnosis
      • Patient does not have conditions likely terminal for opioid prescribing present
    • Patient is not currently prescribed naloxone medications
    • Factors that increase risk for opioid overdose are present:
      • Currently receiving benzodiazepine or other central nervous system depressant medications, or
      • High opioid dosages (MME/day >= 50), or
      • History of substance use disorder, or
      • Diagnosed with sleep-disordered breathing condition
  • Then
    • Incorporate Risk Mitigation Strategies Into Opioid Therapy:
      • Order - Order naxalone
      • Document - Risk mitigation strategy implemented, snooze 3 months
      • Snooze - N/A see comment, snooze 3 months
The following table describes the flowchart decisions and sub-routines for the recommendation
Definition Answer to Proceed Details Data (Terminology) Requirement Profile Path
Order for opioid analgesic with ambulatory misuse potential Yes Order for opioid analgesics with ambulatory misuse potential Opioid analgesics with ambulatory misuse potential MedicationRequest MedicationRequest.medication, and MedicationRequest.category
Opioid review useful? Yes See Opioid Review Useful sub-routine
No evidence of current naloxone medications? Yes Find evidence of naloxone medication prescription (an active medication order for naloxone) Naloxone medications MedicationRequest MedicationRequest.medication, and MedicationRequest.authoredOn
Currently receiving benzodiazepine or other central nervous system depressant medications? Yes Find evidence of benzodiazepine prescription (an active medication order for benzodiazepine or other central nervous system depressant medications) Benzodiazepine or other central nervous system depressant medications MedicationRequest MedicationRequest.medication, MedicationRequest.category, and MedicationRequest.authoredOn
MME (morphine milligram equivalents > 50) Yes Determine MME from existing active prescriptions (recommendation 4 & 5), or future scope; dispensed medications, or patient-reported medications MedicationRequest MedicationRequest.medication, MedicationRequest.category, MedicationRequest.authoredOn, and MedicationRequest.dosageInstruction
History of conditions documenting substance use disorder? Yes Find evidence of conditions documenting substance use in the problem list or past medical history, including history of overdose Conditions documenting substance misuse disorder Condition Procedure Condition.code, Condition.category, and Procedure.code
Diagnosis with a sleep-disordered breathing condition? Yes Find documentation of an active sleep-disordered breathing condition Conditions documenting sleep-disordered breathing TBD TBD

Effective Data Requirements

The following artifacts formalize the description of the logic and behavior defined by this recommendation.

Resource Type Description
2022 CDC Clinical Practice Guideline Recommendation #8 PlanDefinition Event-Condition-Action rule that implements behavior for 2022 CDC Clinical Practice Guideline Recommendation #8
Recommendation #8 - risk factors for opioid-related harms before and during opioid therapy Library Defines the data requirements to support evaluation of recommendation #8
Opioid Terminology Management Knowledge-base Data (OMTK) LibraryLibraryCQL Library that provides logic for implementation of opioid management functionality including Milligram Morphine Equivalents (MME).
Opioid Terminology Management Knowledge-base (OMTK) LibraryLibraryCQL Library that provides logic for implementation of opioid management functionality including Milligram Morphine Equivalents (MME).
Common Opioid Decision Support LogicLibraryCQL Library that provides common logic for the recommendations
Common OpioidCDS Configuration LogicLibraryCQL Library that provides common configuration logic for the recommendations
Common OpioidCDS Routines LogicLibraryCQL Library that provides common routines logic for the recommendations
FHIRHelpers Conversion LogicLibraryCQL Library that defines functions to convert between FHIR data types and CQL system-defined types, as well as functions to support FHIRPath implementation
DescriptionCDS Hooks RequestExpected Response
Patient is 18 or older. Patient has been prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RXNorm 197696) 1 patch per 10 days for 30 days. This will trigger the message "Incorporate into the management plan strategies to mitigate risk; including considering offering naloxone when factors that increase risk for opioid overdose are present." Consider offering naloxone given following risk factor(s) for opioid overdose: Average MME (54.000000 'mg/d') >= 50 mg/day. Request JSON Response JSON
Patient is 18 or older. Patient has been prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RXNorm 197696) 1 patch per 12 days for 30 days. The patient will be excluded and no message will be triggered - an empty set of cards will be returned. Request JSON Response JSON
Patient is 18 or older. Patient has been prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RXNorm 197696) 1 patch per 12 days for 30 days. Patient has also been prescribed Temazepam 20 MG Oral Tablet (RXNorm 104693) 1 tablet per 1 day for 30 days. This will trigger the message “Incorporate into the management plan strategies to mitigate risk; including considering offering naloxone when factors that increase risk for opioid overdose are present. Consider offering naloxone given following risk factor(s) for opioid overdose: concurrent use of benzodiazepine. Request JSON Response JSON
Patient is 18 or older. Patient has been prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RXNorm 197696) 1 patch per 12 days for 30 days. Patient has also been prescribed Naloxone Hydrochloride 0.02 MG/ML Injectable Solution (RXNorm 1191212) 1ml per 1 day for 30 days. The patient will be excluded and no message will be triggered - an empty set of cards will be returned. Request JSON Response JSON
Patient is 18 or older. Patient has been prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RXNorm 197696) 1 patch per 12 days for 30 days. This will trigger the message "Incorporate into the management plan strategies to mitigate risk; including considering offering naloxone when factors that increase risk for opioid overdose are present" Consider offering naloxone given following risk factor(s) for opioid overdose: history of alcohol or drug abuse. Request JSON Response JSON
  • When
    • Order for opioid analgesics with ambulatory misuse potential:
    • Opioid review is useful for this patient:
      • Patient is 18 or over
      • Patient does not have evidence of sickle cell disease
      • Patient does not have findings indicating limited life expectancy
      • Patient does not have orders for therapies indicating end of life care
      • Patient is not undergoing active cancer treatment:
        • Patient has had at least 2 office visits within the past 12 months with an oncology specialist present, or
        • Patient has had at least 2 office visits within the past 12 months with a CDC malignant cancer condition diagnosis
      • Patient does not have conditions likely terminal for opioid prescribing present
    • Patient is not currently prescribed naloxone medications
    • Factors that increase risk for opioid overdose are present:
      • Currently receiving benzodiazepine or other central nervous system depressant medications, or
      • High opioid dosages (MME/day >= 50), or
      • History of substance use disorder, or
      • Diagnosed with sleep-disordered breathing condition
  • Then
    • Incorporate Risk Mitigation Strategies Into Opioid Therapy:
      • Order - Order naxalone
      • Document - Risk mitigation strategy implemented, snooze 3 months
      • Snooze - N/A see comment, snooze 3 months

The following table describes the flowchart decisions and sub-routines for the recommendation
Definition Answer to Proceed Details Data (Terminology) Requirement Profile Path
Order for opioid analgesic with ambulatory misuse potential Yes Order for opioid analgesics with ambulatory misuse potential Opioid analgesics with ambulatory misuse potential MedicationRequest MedicationRequest.medication, and MedicationRequest.category
Opioid review useful? Yes See Opioid Review Useful sub-routine
No evidence of current naloxone medications? Yes Find evidence of naloxone medication prescription (an active medication order for naloxone) Naloxone medications MedicationRequest MedicationRequest.medication, and MedicationRequest.authoredOn
Currently receiving benzodiazepine or other central nervous system depressant medications? Yes Find evidence of benzodiazepine prescription (an active medication order for benzodiazepine or other central nervous system depressant medications) Benzodiazepine or other central nervous system depressant medications MedicationRequest MedicationRequest.medication, MedicationRequest.category, and MedicationRequest.authoredOn
MME (morphine milligram equivalents > 50) Yes Determine MME from existing active prescriptions (recommendation 4 & 5), or future scope; dispensed medications, or patient-reported medications MedicationRequest MedicationRequest.medication, MedicationRequest.category, MedicationRequest.authoredOn, and MedicationRequest.dosageInstruction
History of conditions documenting substance use disorder? Yes Find evidence of conditions documenting substance use in the problem list or past medical history, including history of overdose Conditions documenting substance misuse disorder Condition Procedure Condition.code, Condition.category, and Procedure.code
Diagnosis with a sleep-disordered breathing condition? Yes Find documentation of an active sleep-disordered breathing condition Conditions documenting sleep-disordered breathing TBD TBD

Effective Data Requirements

The following artifacts formalize the description of the logic and behavior defined by this recommendation.

Resource Type Description
2022 CDC Clinical Practice Guideline Recommendation #8 PlanDefinition Event-Condition-Action rule that implements behavior for 2022 CDC Clinical Practice Guideline Recommendation #8
Recommendation #8 - risk factors for opioid-related harms before and during opioid therapy Library Defines the data requirements to support evaluation of recommendation #8
Opioid Terminology Management Knowledge-base Data (OMTK) LibraryLibraryCQL Library that provides logic for implementation of opioid management functionality including Milligram Morphine Equivalents (MME).
Opioid Terminology Management Knowledge-base (OMTK) LibraryLibraryCQL Library that provides logic for implementation of opioid management functionality including Milligram Morphine Equivalents (MME).
Common Opioid Decision Support LogicLibraryCQL Library that provides common logic for the recommendations
Common OpioidCDS Configuration LogicLibraryCQL Library that provides common configuration logic for the recommendations
Common OpioidCDS Routines LogicLibraryCQL Library that provides common routines logic for the recommendations
FHIRHelpers Conversion LogicLibraryCQL Library that defines functions to convert between FHIR data types and CQL system-defined types, as well as functions to support FHIRPath implementation

DescriptionCDS Hooks RequestExpected Response
Patient is 18 or older. Patient has been prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RXNorm 197696) 1 patch per 10 days for 30 days. This will trigger the message "Incorporate into the management plan strategies to mitigate risk; including considering offering naloxone when factors that increase risk for opioid overdose are present." Consider offering naloxone given following risk factor(s) for opioid overdose: Average MME (54.000000 'mg/d') >= 50 mg/day. Request JSON Response JSON
Patient is 18 or older. Patient has been prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RXNorm 197696) 1 patch per 12 days for 30 days. The patient will be excluded and no message will be triggered - an empty set of cards will be returned. Request JSON Response JSON
Patient is 18 or older. Patient has been prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RXNorm 197696) 1 patch per 12 days for 30 days. Patient has also been prescribed Temazepam 20 MG Oral Tablet (RXNorm 104693) 1 tablet per 1 day for 30 days. This will trigger the message “Incorporate into the management plan strategies to mitigate risk; including considering offering naloxone when factors that increase risk for opioid overdose are present. Consider offering naloxone given following risk factor(s) for opioid overdose: concurrent use of benzodiazepine. Request JSON Response JSON
Patient is 18 or older. Patient has been prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RXNorm 197696) 1 patch per 12 days for 30 days. Patient has also been prescribed Naloxone Hydrochloride 0.02 MG/ML Injectable Solution (RXNorm 1191212) 1ml per 1 day for 30 days. The patient will be excluded and no message will be triggered - an empty set of cards will be returned. Request JSON Response JSON
Patient is 18 or older. Patient has been prescribed 72 HR Fentanyl 0.075 MG/HR Transdermal System (RXNorm 197696) 1 patch per 12 days for 30 days. This will trigger the message "Incorporate into the management plan strategies to mitigate risk; including considering offering naloxone when factors that increase risk for opioid overdose are present" Consider offering naloxone given following risk factor(s) for opioid overdose: history of alcohol or drug abuse. Request JSON Response JSON